powered by centersite dot net
Medications
Resources
Basic InformationLatest News
FDA May Limit 'Risk Info' in Direct-to-Consumer TV Drug AdsHealth Tip: Throwing Out Leftover MedicineFDA Announces Recall of Some Liquid Pharmaceutical ProductsIs FDA Taking Close Enough Look at Fast-Tracked Drugs?U.S. Antidepressant Use Jumps 65 Percent in 15 YearsThe Fine Print on Medication Expiration DatesAmericans Taking More Prescription Drugs Than Ever: SurveyInappropriate Med Use High in Cognitively Impaired SeniorsA Reminder That Meds and Grapefruit Don't Always MixAspirin Responsiveness Can Change After Bariatric SurgerySome Medicines Boost Sensitivity to SunPainkiller Prescriptions More Prone to Errors If HandwrittenMedication Mistakes Have Doubled in U.S. Since 2000: StudyMarket Competition Linked to Change in Generic Drug PricesIs Your Child's 'Penicillin Allergy' Real?FDA Seeks to Increase Number of Generic Drugs on MarketWhen Is an Opioid Safe to Take?Lifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyBirth Control Pills Recalled Due to Danger of Unintended PregnancyNew Drugs Show Promise as First to Prevent MigraineMedication Adherence Up With Refill Synchronization ModelModified Vancomycin May Help Fight Bacterial ResistanceScientists Tweak Antibiotic to Boost Power Against 'Superbugs'New Cholesterol Fighting Meds Target Key GeneResearchers Say PDE5 Inhibitors Don't Cause MelanomaNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalU.S. Moves to Avert Shortage of Yellow Fever VaccineOpioid Use by Iraq, Afghanistan War Vets Mirrors Rest of U.S.: StudyApril 29 Is National Prescription Drug Take Back DayERs Administering More Medications IntranasallyFDA Warns Against Children Taking Codeine, TramadolPhysicians Finding Ways to Work Around Cost of Rx MedicationsRuling Out Penicillin Allergy by Testing Inpatients Saves MoneyEpiPen Out-of-Pocket Costs More Than Doubled Over DecadeAACR: Regular Aspirin Use Linked to Lower Cancer MortalityFDA Approves Noctiva Nasal Spray for Nocturnal PolyuriaFDA Approves Odactra for House Dust Mite AllergiesHow Much Melatonin Is Really in That Supplement?Antidepressant Efficacy Varies for Depressive Symptom ClustersDo You Need an Antibiotic?'Off-Label' Antidepressants Common, But Where's the Evidence?Docs More Likely to Prescribe Antibiotics If Patients Expect ThemSimilar Adverse Event Risk for Typical, Atypical AntipsychoticsRx Adherence Reminders No More Effective at 'Fresh Start' DatesThink You're Allergic to Penicillin? Check AgainExcessive FDA Regulation Driving High Drug PricesOutcomes-Based Pricing Suggested for New, Costly DrugsPrices Skyrocket on Drugs Widely Used by Seniors: Report
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

'Off-Label' Antidepressants Common, But Where's the Evidence?

HealthDay News
by By Alan Mozes
HealthDay Reporter
Updated: Feb 22nd 2017

new article illustration

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- Doctors often prescribe antidepressants to tackle conditions like migraine headaches for which they aren't technically approved. Now, researchers say such "off-label" usage mostly occurs without clear scientific evidence backing up the treatments.

A new Canadian study found that almost one-third of antidepressants are prescribed for pain, insomnia, migraine or other unapproved uses.

But just 16 percent of those off-label prescriptions were found to be supported by strong research.

Study lead author Jenna Wong described the findings as "eye-opening" but in line with the findings of prior investigations.

Wong, a doctoral candidate in epidemiology, biostatistics, and occupational health at McGill University in Montreal, said she hopes the findings raise awareness among doctors.

"Some physicians may not be aware that certain off-label antidepressant uses are not evidence-based, especially if the broader community of physicians prescribes antidepressants for these off-label uses so frequently that it seems like the norm," she said.

Doctors prescribe off-label for other reasons as well.

In cases where the approved medication carries major side effects -- such as insomnia drugs for older patients -- "physicians may prescribe antidepressants instead of thinking that these drugs are safer," Wong said.

The new findings stem from an analysis of more than 100,000 antidepressant prescriptions issued in Quebec, Canada, between 2003 and 2015. They were written by 174 Quebec doctors.

According to the study, trazodone was the most common off-label use for antidepressants. It's often prescribed to help people sleep.

In terms of class of drugs, tricyclic antidepressants like amitriptyline were the most likely to be prescribed off-label. This is a common migraine treatment.

Antidepressants known as selective-serotonin reuptake inhibitors (SSRIs) -- including fluoxetine (Prozac) and sertraline (Zoloft) -- were less likely to be used off-label. That was also the case for drugs like venlafaxine (Effexor), which is a serotonin-noradrenaline reuptake inhibitor (SNRI), the study found.

The researchers said 44 percent of the alternative drugs lacked any strong research backing up the effectiveness of the intended off-label purpose. Another 40 percent lacked evidence for the medicine at hand, but did have strong evidence supporting use of a similar drug in the same class for the intended off-label usage.

Wong said she expected "trends to be similar" in the United States, although she can't be sure.

The results were published online Feb. 21 in BMJ.

The author of an accompanying journal editorial, Daniel Morales, pointed out that off-label use "has always happened."

"Some off-label prescribing has strong evidence, but pharmaceutical companies may not apply for a license for a new indication because it is a complex and expensive process," said Morales, a fellow in the school of medicine at the University of Dundee in Dundee, Scotland.

The bottom line is that "the strength of evidence for using an antidepressant for a particular patient or condition" is equally important whether the antidepressant is used "on" or "off" label, said Morales.

Dr. David Katz, director of the Yale University Prevention Research Center in New Haven, Conn., cautioned against painting off-label prescribing in a broadly negative light.

The practice "invites concern and caution, but does not necessarily indicate poor choices," he explained.

"I have prescribed off-label many times myself, and generally it was because my patient needed me to get creative to figure out how to help them when the more obvious choices had failed for various reasons," Katz said.

He agreed that because the regulatory approval process is so expensive, drug companies often stop after acquiring approval in one area of use.

"But to be clear," he added, "a product might work just as intended (or) hoped, even if there is no multinational randomized trial in the thousands to prove it," Katz added.

Wong and her team suggested more research is needed to examine the effectiveness of off-label antidepressant uses.

Also, "when evidence is lacking, we encourage physicians to prescribe conservatively or engage with their patients in a shared decision-making process to decide whether taking an antidepressant is the right choice for them," Wong added.

More information

There's more on off-label prescribing at the U.S. Food and Drug Administration.